Jiangsu Aidea Pharmaceutical Co Ltd Total Liabilities
Jiangsu Aidea Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Jiangsu Aidea Pharmaceutical Co Ltd (688488) has total liabilities worth CN¥1.00 Billion CNY (≈ $146.43 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 688488 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jiangsu Aidea Pharmaceutical Co Ltd (2016–2025)
Total liabilities of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025. This chart illustrates how Jiangsu Aidea Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Jiangsu Aidea Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Aidea Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chengdu Guibao Science Tech
SHE:300019
|
China | CN¥1.15 Billion |
|
MorningStar Partners, L.P.
NYSE:TXO
|
USA | $487.10 Million |
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
China | CN¥672.43 Million |
|
Thanh Thanh Cong Tay Ninh JSC
VN:SBT
|
Vietnam | ₫26.26 Trillion |
|
Bioventus Inc
NASDAQ:BVS
|
USA | $395.93 Million |
|
JBG SMITH Properties
NYSE:JBGS
|
USA | $2.70 Billion |
|
PSI Software AG
F:PSAN
|
Germany | €227.15 Million |
|
Paul Hartmann AG
F:PHH2
|
Germany | €938.79 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Jiangsu Aidea Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Jiangsu Aidea Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Jiangsu Aidea Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Jiangsu Aidea Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Aidea Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2025)
The table below shows the annual total liabilities of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥839.37 Million ≈ $122.83 Million |
+4.60% |
| 2024-12-31 | CN¥802.48 Million ≈ $117.43 Million |
+29.22% |
| 2023-12-31 | CN¥621.03 Million ≈ $90.88 Million |
+36.12% |
| 2022-12-31 | CN¥456.23 Million ≈ $66.76 Million |
+265.52% |
| 2021-12-31 | CN¥124.82 Million ≈ $18.26 Million |
+43.52% |
| 2020-12-31 | CN¥86.97 Million ≈ $12.73 Million |
-61.30% |
| 2019-12-31 | CN¥224.74 Million ≈ $32.89 Million |
+20.68% |
| 2018-12-31 | CN¥186.24 Million ≈ $27.25 Million |
+28.31% |
| 2017-12-31 | CN¥145.14 Million ≈ $21.24 Million |
+1.39% |
| 2016-12-31 | CN¥143.16 Million ≈ $20.95 Million |
-- |
About Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins. The company also provides anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules… Read more